Men with metastatic castration-resistant prostate cancer (mCRPC) who receive chemotherapy as part of their treatment sequence have longer survival compared with those who do not, according to the findings of a real-world data analysis presented at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.
Of 1961 men with mCRPC identified using the Optum electronic health record dataset, 823 (41.9%) received chemotherapy (docetaxel or cabazitaxel) and 1138 received abiraterone or enzalutamide and no chemotherapy as their first observed line of therapy. Median overall survival time was 25.4 months for chemotherapy recipients and 22.4 months for those not receiving chemotherapy, Alicia Morgans, MD, of Northwestern University Feinberg School of medicine in Chicago, and colleagues reported in a poster presentation. The no-chemotherapy group had a significant 24% increased risk of death. The chemotherapy group had a significantly higher 18-month survival rate than the no-chemotherapy group (65.4% vs 58.4%).
The study also revealed that patients receiving chemotherapy were younger and had more lines of treatment than those not receiving chemotherapy, but they had more comorbidities and pain medication usage and a higher proportion of liver, lung, and lymph node metastases, according to the investigators.
Morgans A, Divan HA, Birtle A, et al. Real-world analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence. Presented at the European Society for Medical Oncology 2019 Congress held September 27 to October 1 in Barcelona, Spain. Poster 856P